EMA Recommends Granting a Marketing Authorisation for Camizestrant By Ogkologos - June 5, 2026 123 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations Source RELATED ARTICLESMORE FROM AUTHOR Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength Could Functional Precision Medicine Be the New Precision Oncology? MOST POPULAR Techniques for Successful Glucose Daddies and Babies Relationships September 4, 2022 Doctors Think Woman Has A Brain Tumor, But Then They Open... June 17, 2019 Osimertinib Improves Survival in Advanced Lung Cancer with EGFR Mutations December 12, 2019 More than 65,000 people are left waiting to find out if... May 8, 2022 Load more HOT NEWS Breast Cancer Survivor Comes First Woman In The World To Give... Italian Association of Oncology Nurses Maps the Situation of Cancer Patients... Breast Cancer Survivor Invents Warming Bra Insert to Combat Cold Feeling... Spurred by Survivors, Researchers Are Revisiting Cancer Drug Doses
